AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC

Journal of Gastroenterology

Volumn 45, Issue 12, 2010, Pages 1272-1282

  Yamamoto, Kentaroh ^a   Imamura, Hiroshi ^a   Matsuyama, Yutaka ^a   Kume, Yukio ^a   Ikeda, Hitoshi ^a   Norman, Gary L ^b   Shums, Zakera ^b   Aoki, Taku ^a   Hasegawa, Kiyoshi ^a   Beck, Yoshifumi ^a   Sugawara, Yasuhiko ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

AFP; AFP L3; DCP; GP73; HCC

Indexed keywords

ALPHA FETOPROTEIN; CELL PROTEIN; DECARBOXYPROTHROMBIN; FETOPROTEIN; GOLGI PROTEIN 73; LENS CULINARIS AGGLUTININ REACTIVE FRACTION OF ALPHA FETOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PROTHROMBIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78651317489     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0278-5     Document Type: Article

References (40)

1. HB El-Serag 2004 Hepatocellular carcinoma: recent trends in the United States Gastroenterology 127 S27 S34 10.1053/j.gastro.2004.09.013 15508094 (Pubitemid 39423367)
2. J Bruix M Sherman Practice Guidelines Committee, American Association for the Study of Liver Diseases 2005 Management of hepatocellular carcinoma Hepatology 42 1208 1236 10.1002/hep.20933 16250051 (Pubitemid 43112690)
3. HA Liebman BC Furie MJ Tong RA Blanchard KJ Lo SD Lee, et al. 1984 Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma N Eng J Med 310 1427 1431 1:STN:280: DyaL2c7ptFersw%3D%3D 10.1056/NEJM198405313102204
4. F Nomura M Ishijima K Kuwa N Tanaka T Nakai K Ohnishi 1999 Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma Am J Gastroenterol 94 650 654 1:CAS:528:DyaK1MXitV2ku70%3D 10.1111/j.1572-0241.1999. 00930.x 10086646
5. Y Aoyagi M Isemura Y Suzuki C Sekine K Soga T Ozaki, et al. 1985 Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma Lancet 2 1353 1354 1:STN:280:DyaL28%2FmsVGlsg%3D%3D 10.1016/S0140-6736(85)92643-1 2415789
6. K Taketa Y Endo C Sekiya K Tanikawa T Koji H Taga, et al. 1993 A collaborative study for the evaluation of lectin-reactive alpha-fetoprotein in early detection of hepatocellular carcinoma Cancer Res 53 5419 5423 1:CAS:528:DyaK2cXltFCjsg%3D%3D 7693340
7. JA Marrero PR Romano O Nikolaeva L Steel A Mehta CJ Fimmel, et al. 2005 GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma J Hepatol 43 1007 1012 1:CAS:528:DC%2BD2MXht1egsrvE 10.1016/j.jhep.2005.05.028 16137783 (Pubitemid 41627986)
8. JS Hu DW Wu S Liang XY Miao 2009 GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population Med Oncol 27 339 345 10.1007/s12032-009- 9215-y 19399652
9. MF Yuen CL Lai 2005 Serological markers of liver cancer Best Pract Res Clin Gastroenterol 19 91 99 1:CAS:528:DC%2BD2MXitFCjtLs%3D 10.1016/j.bpg.2004. 10.003 15757806 (Pubitemid 40331499)
10. M Makuuchi T Kosuge T Takayama S Yamazaki T Kakazu S Miyagawa, et al. 1993 Surgery for small liver cancers Semin Surg Oncol 9 298 304 1:STN:280:DyaK2c%2FitlKltw%3D%3D 10.1002/ssu.2980090404 8210909
11. T Takayama T Sekine M Makuuchi S Yamasaki T Kosuge J Yamamoto, et al. 2000 Adoptive immunotherapy to lower postsurgical recurrence rate of hepatocellular carcinoma: a randomized trial Lancet 356 802 807 1:STN:280:DC%2BD3cvmvVSltg%3D%3D 10.1016/S0140-6736(00)02654-4 11022927
12. K Shimizu T Taniichi S Satomura S Matsuura H Taga K Taketa 1993 Establishment of assay kits for the determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis Clin Chim Acta 214 3 12 1:CAS:528:DyaK3sXhs1CmtL4%3D 10.1016/0009-8981(93)90297-H 7680970 (Pubitemid 23055363)
13. H Toyoda T Kumada Y Kaneoka Y Osaki T Kimura A Arimoto, et al. 2008 Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC J Hepatol 49 223 232 1:CAS:528:DC%2BD1cXotlWqtr8%3D 10.1016/j.jhep.2008.04.013 18571271
14. FA Durazo LM Blatt WG Corey JH Lin S Han S Saab, et al. 2008 Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma J Gastroenterol Hepatol 23 1541 1548 1:CAS:528:DC%2BD1cXhtlOmu7rO 10.1111/j.1440-1746.2008. 05395.x 18422961
15. J Bruix M Sherman JM Llovet M Beaugrand R Lencioni AK Burroughs, et al. 2001 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 421 430 1:STN:280:DC%2BD3MrksFCmtg%3D%3D 10.1016/S0168-8278(01) 00130-1 11592607 (Pubitemid 32844200)
16. Liver Cancer Study Group In Japan. The general rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara; 2008.
17. CE Metz 1978 Basic principles of ROC analysis Semin Nucl Med 8 283 298 1:STN:280:DyaE1M3kvVyltQ%3D%3D 10.1016/S0001-2998(78)80014-2 112681
18. R Tateishi H Yoshida Y Matsuyama N Mine Y Kondo M Omata 2008 Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review Hepatol Int 2 17 30 10.1007/s12072-007-9038-x 19669276 (Pubitemid 351250400)
19. R Tateishi S Shiina H Yoshida T Teratani S Obi N Yamashiki, et al. 2006 Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers Hepatology 44 1518 1527 1:CAS:528: DC%2BD2sXislKksw%3D%3D 10.1002/hep.21408 17133456 (Pubitemid 44953657)
20. M Makuuchi N Kokudo S Arii S Futagawa S Kaneko S Kawasaki, et al. 2008 Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan Hepatol Res 38 37 51 10.1111/j.1872-034X.2007.00216.x 18039202 (Pubitemid 350182575)
21. PJ Johnson 2001 The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma Clin Liver Dis 5 145 159 1:STN:280:DC%2BD3M3gtlygsw%3D%3D 10.1016/S1089-3261(05)70158-6 11218912
22. K Hasegawa H Imamura M Ijichi Y Matsuyama K Sano Y Sugawara, et al. 2008 Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462) J Gastrointest Surg 12 858 866 10.1007/s11605-007-0464-9 18202893
23. Y Gu W Chen Y Zhao L Chen T Peng 2009 Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases Ann Clin Biochem 46 38 43 1:CAS:528:DC%2BD1MXjsV2htL8%3D 10.1258/acb.2008.008088 19008260
24. MO Riener F Stenner H Liewen C Soll S Breitenstein BC Pestalozzi, et al. 2009 Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its values as a serum marker in hepatocellular carcinomas Hepatology 49 1602 1609 1:CAS:528:DC%2BD1MXlslKmu78%3D 10.1002/hep.22843 19291786
25. A Leerapun SV Suravarapu JP Bida RJ Clark EL Sanders TA Mettler, et al. 2007 The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population Clin Gastroenterol Hepatol 5 394 402 1:CAS:528:DC%2BD2sXkslSltr8%3D 10.1016/j.cgh.2006.12.005 17368240 (Pubitemid 46401522)
26. RK Sterling L Jeffers F Gordon M Sherman AP Venook KR Reddy, et al. 2007 Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis Am J Gastroenterol 102 2196 2205 10.1111/j.1572-0241.2007. 01405.x 17617202 (Pubitemid 47493844)
27. JA Marrero GL Su W Wei M Sherman AP Venook KR Reddy, et al. 2003 Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients Hepatology 37 1114 1121 1:CAS:528:DC%2BD3sXktVWnsLs%3D 10.1053/jhep.2003.50195 12717392 (Pubitemid 36538688)
28. CS Wang CL Lin HC Lee KY Chen MF Chiang HS Chen, et al. 2005 Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma World J Gastroenterol 11 6115 6119 1:CAS:528:DC%2BD28XhsVentLs%3D 16273636
29. S Nakamura K Nouso K Sakaguchi YM Ito Y Ohashi Y Kobayashi, et al. 2006 Sensitivity and specificity of des-gammma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma varies according to tumor size Am J Gastroenterol 101 2038 2043 1:CAS:528:DC%2BD28XhtVyisLzO 10.1111/j.1572-0241. 2006.00681.x 16848811 (Pubitemid 44337629)
30. Y Kim do YH Paik SH Ahn YJ Youn JW Choi JK Kim, et al. 2007 PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection Oncology 72 52 57 10.1159/000111707 18087182 (Pubitemid 350256665)
31. K Yamamoto H Imamura Y Matsuyama K Hasegawa Y Beck Y Sugawara, et al. 2009 Significance of alpha-fetoprotein and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy Ann Surg Oncol 16 1795 1804 10.1245/s10434-009-0618-y
32. JA Marrero Z Feng Y Wang MH Nguyen AS Befeler LR Roberts, et al. 2009 Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma Gastroenterology 137 110 118 1:CAS:528:DC%2BD1MXovFOgsbs%3D 10.1053/j.gastro.2009.04.005 19362088
33. C Kagebayashi I Yamaguchi A Akinaga, et al. 2009 Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis Anal Biochem 388 306 311 1:CAS:528:DC%2BD1MXkvVWnsrY%3D 10.1016/j.ab.2009.02.030 19250915
34. H Imamura Y Matsuyama Y Miyagawa K Ishida R Shimada S Miyagawa, et al. 1999 Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma Br J Surg 86 1032 1038 1:STN:280:DyaK1MzptVagsg%3D%3D 10.1046/j.1365-2168.1999.01185.x 10460639 (Pubitemid 29387069)
35. K Oishi T Itamoto H Amano S Fukuda H Ohdan H Tashiro, et al. 2007 Clinicopathologic features of poorly differentiated hepatocellular carcinoma J Surg Oncol 95 311 316 10.1002/jso.20661 17326126 (Pubitemid 46355507)
36. H Okuda T Nakanishi K Takatsu A Saito N Hayashi M Yamamoto, et al. 2002 Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone J Gastroenterol Hepatol 17 772 778 1:CAS:528: DC%2BD38XntlSqtrc%3D 10.1046/j.1440-1746.2002.02806.x 12121507 (Pubitemid 34779738)
37. T Tada T Kumada H Toyoda S Kiriyama Y Sone M Tanikawa, et al. 2005 Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma Liver Int 25 848 853 1:CAS:528:DC%2BD2MXpsVant7k%3D 10.1111/j.1478-3231.2005.01111.x 15998436 (Pubitemid 41038666)
38. H Miyaaki O Nakashima M Kurogi K Eguchi M Kojiro 2007 Lens cullinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma J Gastroenterol 42 962 968 1:CAS:528:DC%2BD2sXhsVelsbzN 10.1007/s00535-007-2117-x 18085353
39. S Inoue A Nakao A Harada T Nonami H Takagi 1994 Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma Am J Gastroenterol 89 2222 2226 1:STN:280:DyaK2M%2Fmslynsw%3D%3D 7526679
40. T Suehiro K Sugimachi T Matsumata H Itasaka A Taketomi T Maeda 1994 Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein Cancer 73 2464 2471 1:STN:280:DyaK2c3ivVChug%3D%3D 10.1002/1097-0142(19940515)73:10<2464::AID- CNCR2820731004>3.0.CO;2-9 7513601 (Pubitemid 24155520)